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Abstract: Background: Type 2 diabetes mellitus (T2DM) is accompanied by chronic low-grade 
inflammation, with an imbalance in the secretion of adipokines and, worsening insulin resistance. 
Supplementation with n-3 PUFA in T2DM decreases inflammatory markers, the purpose of the 
study was to investigate the effect of n-3 PUFA supplementation on adipokines, metabolic control, 
and lipid profile in T2DM Mexican adults. Methods: In a randomized, single-blind, placebo-
controlled pilot study, 54 patients with T2DM received 520 mg of DHA + EPA-enriched fish-oil 
(FOG) or a placebo (PG) daily. Baseline and 24-week anthropometric and biochemical 
measurements included glucose, insulin, glycosylated hemoglobin (Hb1Ac), leptin, adiponectin, 
resistin, and lipid profile; n-3 PUFA intake was calculated in g/day. Results: Waist circumference 
and blood glucose showed significant reductions in the FOG group (p = 0.001 and p = 0.011, 
respectively). Hb1Ac (p = 0.009 and p = 0.004), leptin (p < 0.000 and p < 0.000), and leptin/adiponectin 
ratio (p < 0.000 and p < 0.000) decreased significantly in both groups after 24 weeks (FOG and PG 
respectively). Serum resistin (FOG p < 0.000 and PG p = 0.001), insulin (FOG p < 0.000 and PG p < 
0.000), and HOMA-IR (FOG p = 0.000 and PG p < 0.000) increased significantly in both groups. FOG 
had an overall improvement in the lipid profile with a significant decrease in triacylgycerols (p = 
0.002) and atherogenic index (p = 0.031); in contrast, the PG group had increased total cholesterol (p 
< 0.000), non-HDL cholesterol (p < 0.000), and atherogenic index (p = 0.017). Conclusions: We found 
a beneficial effect of n-3 PUFA supplementation on waist circumference, glucose, Hb1Ac, leptin, 
leptin/adiponectin ratio, and lipid profile, without significant changes in adiponectin, and increases 
in resistin, insulin, and HOMA-IR in both groups. 
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1. Introduction 
Type 2 diabetes mellitus (T2DM) is one of the most prevalent chronic diseases around the world, 
with an increase in its prevalence due to the increase in its risk factors such as obesity and physical 
inactivity [1]. According to the National Health and Nutrition Survey, in 2012, in Mexico there were 
6.4 million people with T2DM, which means an increase in prevalence from 7% in 2006 to 9.2% in 
2012 [2]. T2DM is characterized by impaired pancreatic β-cell function that causes impaired insulin 
secretion and insulin resistance (IR) mainly in liver, muscle, and adipose tissue [3]. 
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It is well recognized that the actively secreted products of adipose tissue known as adipokines 
can modulate different functions [4]; adipokines play a pivotal role in the regulation of whole-body 
metabolism, as well as in inflammatory and immune responses, and are considered a link between 
obesity and the development of T2DM [5].  
Adiponectin is a collagen‐like protein exclusively expressed in adipose tissue [6], which 
possesses potent antidiabetic and anti-inflammatory properties [7]. In humans, plasma adiponectin 
levels are closely related to whole-body insulin sensitivity [8] and are correlated negatively with IR 
and T2DM. Prospective and longitudinal studies have indicated that lower adiponectin levels are 
associated with a higher incidence of T2DM [4]. Adiponectin regulates glucose and lipid metabolism 
through the reduction of fat storage (lipogenesis) and the promotion of fat utilization (fatty acid 
oxidation) [9].  
Leptin is a cytokine‐like molecule secreted by adipose tissue which regulates adipose tissue mass 
and body weight by inhibiting food intake and stimulating energy expenditure [6], thus maintaining 
energy homeostasis. Leptin correlates directly with adipose tissue mass. Obesity and T2DM are 
associated with increased plasma leptin levels, which fail to correct hyperglycemia in these patients 
because of the presence of leptin resistance [5], and these elevated plasma leptin levels are associated 
with IR, independent of obesity and insulin sensitivity [10].  
In humans, resistin is mainly secreted by macrophages and monocytes and by organs such as 
spleen and bone marrow [11]. Since its discovery, resistin has been related to obesity and IR in many 
animal experiments, but the application of these findings to human studies has been difficult to 
determine. However, studies in humans have shown that serum resistin levels are higher in obese 
patients with T2DM compared with non-diabetic obese and that mRNA levels of resistin are higher 
in female patients with T2DM compared to healthy women [12].  
Dyslipidemias are very common in type 2 diabetes mellitus and are the cause of cardiovascular 
disease in uncontrolled patients. Hypertriacylglyceridemia as well as low HDL-cholesterol 
concentrations, together with high LDL- and non-HDL-cholesterol is a common lipid profile pattern 
observed in subjects with diabetes [13–16].  
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are polyunsaturated fatty acids 
found at high levels in fish oils [17]. Accumulating evidence suggests that n-3 PUFAs from fish oil 
may counteract the adipokine dysregulation that occurs in obesity and its related diseases like T2DM 
[9], but it is not well established if the consumption of n-3 PUFAs affects circulating adiponectin, 
resistin, and leptin in humans; the results are inconclusive [18]. Furthermore, research in humans and 
animal models show a lipid normalizing effect of PUFA supplementation [19,20].  
For these reasons, we undertook a pilot study with the aim of investigating the effect of a six-
month supplementation trial with n-3 PUFAs on adiponectin, resistin, leptin, and the lipid profile in 
adults with T2DM from Toluca, Mexico. 
2. Materials and Methods 
2.1. Study Design 
This study was a randomized, single-blind and placebo-controlled pilot study conducted in 
eight Urban Public Health Centers (UPHC) in Toluca, Mexico, from February to September 2015. The 
inclusion criteria were the following: men and women with T2DM, between 25 and 60 years, without 
other chronic diseases such as hypertension, arthritis, kidney disease, cancer, and HIV, with a BMI ≤ 
29.9, without fish allergies or insulin treatment, and not lactating or pregnant. 
2.2. Methods 
Sixty-five Mexican subjects with T2DM were enrolled from the eight UPHC in Toluca as follows: 
Capultitlán (n = 1), Emiliano Zapata (n = 6), Nueva Oxtototitlán (n = 2), Reforma (21), Seminario (3), 
Tlacotepec (1), San Diego de los Padres (n = 16), and Ejido de la Y (n = 15). The 65 subjects were 
randomly and blindly separated into an experimental group (fish oil group: FOG) of 34 patients (10 
males, 24 females) and a control group (placebo group: PG) of 31 patients (5 males, 26 females). The 
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majority of patients were medicated with Glibenclamide plus Metformin or Metformin alone and 
were controlled by their family practitioner, we did not give them additional dietary or lifestyle 
advice; we only asked them to continue with their regular medication and diet.  
Written informed consent was given to all participants. The study was approved by the Research 
and Ethics Committee of the Universidad Autónoma del Estado de Mexico and the Institute for 
Health of the State of Mexico’s Research and Education Coordination. The protocol was conducted 
following the regulations of the Helsinki Declaration of 1975 and its amendment of 2013, as well as 
the principles for experiments with human beings from the Nüremberg Code for medical ethics. 
Individual data is being maintained confidential. 
Once obtained the sample, the baseline evaluation was performed as follows: 
Anthropometric evaluation: 
All measurements were recorded with light clothes and height without shoes by a trained 
nutritionist who was previously standardized. Weight was measured in a TANITA®  scale (Mod. 
1631) and was registered in kg; height was measured in cm using a portable SECA 206 stadiometer; 
the percentage of body fat was obtained by electrical bioimpedance with the same TANITA scale; 
body mass index (BMI) was calculated as body weight in kilograms divided by the square of height 
in meters. Waist and hip circumferences were measured with a Gülick™ fiberglass tape and the 
waist/hip ratio was calculated. 
Biochemical evaluation: 
After an overnight fast (≥12 h), collection of a venous blood sample into an 8.5 mL tiger-top tube 
containing gel and clotting activator for the subsequent biochemical analysis of glucose, insulin, 
adipokines, and lipid profile was undertaken. Another venous blood sample in a 3 mL tube with 
EDTA for the analysis of glycosylated hemoglobin was also obtained.  
Serum was obtained after centrifugation at 900 g or 3400 rpm for 10 min at 4 °C, within 30 min 
after blood sample collection; serum samples for glucose and lipid profile were processed within one 
hour, and the rest of the samples were aliquoted and stored at −80 °C until assayed. 
Serum glucose, triacylglycerols, total cholesterol, HDL-cholesterol, LDL-cholesterol, and 
glycosylated hemoglobin levels (in total blood) were measured by enzymatic colorimetric assays in 
the auto-analyzer Selectra II (ROCHE™), using reagents from RANDOX™ (Cat. GL1611, Cat. Tr213, 
Cat. CHO215, Cat. CH3811A, Cat. CH3811B and Cat. HA3830A). Non-HDL-cholesterol was 
calculated by difference (total cholesterol − HDL-cholesterol).  
Serum levels of insulin were measured with a Human Insulin ELISA kit from EMD Millipore 
Corporation®  (Cat. # EZHI-14K) according to the manufacturer s´ instructions. We evaluated IR with 
glucose and insulin concentrations using the Homeostatic model assessment as follows:  
HOMA-IR = (fasting insulin (µU/mL)) × (fasting glucose (mg/dL))/405 [21].  
Commercially available kits from Merck Millipore®  (Cat. # HADK1MAG-61K and 
HADK2MAG-61K) were used to measure the serum levels of adiponectin, resistin, and leptin in the 
Luminex®  100™ analyzer by luminometry according to the manufacturer’s recommended protocols. 
2.3. Supplementation 
The supplementation period started after basal evaluation. Patients took two softgels per day of 
the assigned supplement for 24 weeks. Each 1.4 g n-3 PUFAs softgel contained a combination of 160 
mg of eicosapentaenoic acid (EPA) with 100 mg of docosahexaenoic acid (DHA) from fish oil, so the 
total daily oral dose was 520 mg of n-3 PUFAs (320 mg of EPA and 200 mg of DHA, 2 g of total fat, 
1.2 mg of vitamin E, gelatin and glycerine) during the six months of intervention. PUFA supplements 
were purchased from General Nutrition Centers™. The placebo softgels were identical to the n-3 
PUFAs softgels in appearance and contained cornstarch (1 g carbohydrates and 1.7 mg of sodium per 
softgel). 
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2.4. Follow-up 
After basal evaluation, patients were monitored by 6 monthly visits, in which they received their 
corresponding supplement and were followed-up every two weeks by telephone to make sure that 
they were taking their capsules, as well as to remind them not to change their habitual diet, 
medication, or physical activity regimes. 
2.5. Diet Analysis 
A trained nutritionist performed 24-h recalls, one at the beginning and one at the end of the 
study to analyze the diet. The dietary nutrient intake and the consumption of polyunsaturated fatty 
acids were calculated in grams and percentages using DIAL®  (ver 3.3.2., Universidad Complutense, 
Madrid, Spain) software. In the final 24 h recalls of the FOG, we added the nutritional composition 
of n-3 PUFA softgels.  
2.6. Statistical Analysis 
Data were expressed as mean ± SD. To compare differences in the same group after intervention, 
paired t-test was used for parametric variables and Wilcoxon signed rank test for non-parametric 
variables. In the diet analysis, unpaired two-sample t-test was used to compare differences between 
groups in a parametric way and a Mann–Whitney U-test for non-parametric data. Normality of data 
was assessed by the Kolmogorov–Smirnoff test. All analyses were performed using the statistical 
software SPSS (version 19.0; SPSS Inc., Chicago, IL, USA). A p-value < 0.05 was considered statistically 
significant. 
3. Results 
During the study, 10 subjects, 4 in the omega-3 group and 6 in the placebo group, were 
eliminated for not completing the six-month supplementation for personal reasons, and the drop-out 
rate in both groups was less than 20%. When analyzing the causes for drop-out, it is important to 
note that all patients had low-education and socioeconomic levels, and even though we tried to reach 
them by phone or house-visits, they were not located either to follow-up or to obtain data at the end 
of the trial. We analyzed basal data for differences between those who dropped out and those who 
stayed, and there were no significant differences between groups that indicated that they stopped 
attending due to the variables we were evaluating.  
Age, gender distribution, and diabetes duration were similar between groups without 
significant differences; in the FOG, 7 subjects were males, and 22 were females; in the PG, 5 subjects 
were males and 20 were females. The mean age of the FOG was of 50.4 ± 6.3 years, while in the PG it 
was 48.1 ± 6.8 years (p = 0.208), and the average time of diabetes duration was of 6.6 ± 5.0 years in the 
FOG and of 6.5 ± 5.8 years in the PG (p = 0.954).  
In anthropometric measurements, only the FOG showed a significant decrease in waist 
circumference after supplementation (p = 0.001) (Table 1). No significant changes in body weight (p = 
0.250 and 0.578), BMI (p = 0.278 and 0.485), body fat (p = 0.889 and 0.614), and waist/hip ratio (p = 0.288 
and 0.076) were observed in FOG and PG, respectively, after intervention. 
Table 1. Anthropometric measurements. 
 Fish Oil Group (n = 29)  Placebo Group (n = 25)  
Variables Basal Final p Basal Final p 
Body weight (kg) 63.0 ± 9.3 62.7 ± 9.4  0.250 60.2 ± 6.4 60.0 ± 7.3 0.578 
BMI (kg/m2) 25.6 ± 2.4 25.4 ± 2.7 0.278 26.0 ± 1.6 25.9 ± 2.0 0.485 
Body fat (%) 30.9 ± 9.1 31.1 ± 7.2 0.889 29.9 ± 5.3 30.4 ± 6.1  0.614 
Waist circumference (cm) 86.4 ± 7.6 83.1 ± 6.2 0.001 83.2 ± 5.3 83.1 ± 6.1 0.893 
Waist/hip ratio 0.89 ± 0.05 0.90 ± 0.05 0.288 0.90 ± 0.05 0.92 ± 0.04 0.076 
BMI: body mass index. Paired t-test was performed to compare differences in time (before and after 
supplementation). A p-value < 0.05 was considered statistically significant, marked in bold numbers.  
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At baseline, there was only a significant difference between groups in serum resistin levels (p = 
0.006). The results of biochemical analysis are summarized in Table 2. Glucose serum levels only 
showed a significant decrease in FOG (p = 0.001), and there were significant reductions in 
glycosylated hemoglobin (p = 0.009 and p = 0.004), leptin (p = 0.000 and p = 0.000), and 
leptin/adiponectin ratio in both groups (FOG and PG, respectively). Adiponectin did not show 
significant changes (p = 0.177 for FOG and p = 0.563 for PG). Contrary to expected, resistin showed a 
significant increase in both groups (p = 0.000 for FOG and p = 0.001 for PG). With respect to IR, there 
were significant increases in insulin serum levels (p = 0.000 for FOG and p = 0.000 for PG) and in 
HOMA-IR (p = 0.000 for FOG and p = 0.000 for PG).  
Table 2 shows changes in lipid profile indicators, FOG significantly decreased triacylglycerides 
(p < 0.01) and the atherogenic index (p < 0.05), whereas the placebo group showed a statistically 
significant increase in total cholesterol (p < 0.000), non-HDL-cholesterol (p < 0.000), and the 
atherogenic index (p < 0.05).  
The results of diet analysis are shown in Table 3. The FOG showed a significant increase in total 
omega-3 fatty acids (p < 0.001), particularly in EPA and DHA (p < 0.000); n-6 to n-3 ratio decreased 
from 16:1 to 10:1 (p < 0.05). The placebo group showed a statistically significant increase in protein 
and monounsaturated fatty acid intake (p < 0.05). No differences were found in any other nutrient 
analyzed. 
Table 2. Biochemical measurements. 
 Omega-3 (n = 29)  Placebo (n = 25)  
Variables Basal Final  p Basal Final p 
Glucose (mg/dL) ‡ 177.2 ± 68.4 156.1 ± 69.4 0.011 184.6 ± 71.1 183.3 ± 53.3 0.326 
Glycosylated hemoglobin (%) †  9.6 ± 3.1 8.2 ± 1.9 0.009 10.0 ± 2.1 9.0 ± 1.8 0.004 
Adiponectin (µg) ‡ 23.6 ± 20.3 24.5 ± 13.0 0.177 22.8 ± 10.5 24.3 ± 13.3 0.563 
Leptin (ng) † 21.7 ± 15.5 3.9 ± 2.5 0.000 18.4 ± 13.2 3.5 ± 2.3 0.000 
Resistin (ng) ‡ 30.2 ± 14.0 65.9 ± 23.4 0.000 39.2 ± 12.5 61.3 ± 20.6 0.000 
Leptin/adiponectin ratio † 1.3 ± 1.2 0.24 ± 0.26 0.000 0.88 ± 0.68 0.17 ± 0.12 0.000 
Insulin µU/mL ‡ 7.6 ± 3.0 14.2 ± 8.2 0.000 6.5 ± 1.6  10.2 ± 3.3  0.000 
HOMA-IR ‡ 3.1 ± 1.3 5.3 ± 3.8 0.000 2.9 ± 1.2 4.4 ± 1.6 0.000 
Total Cholesterol (mg/dL) † 203.38 ± 33.72 199.10 ± 47.63 0.542 180.32 ± 30.56 209.75 ± 36.80 0.000 
Triacylglycerides (mg/dL) † 186.24 ± 85.58 137.28 ± 65.39 0.002 269.40 ± 169.30 251.20 ± 149.76 0.503 
HDL-Cholesterol (mg/dL) † 43.52 ± 7.95 48.13 ± 14.59 0.076 38.35 ± 9.51 40.01 ± 9.28 0.384 
LDL-Cholesterol (mg/dL) † 131.00 ± 34.66 129.82 ± 44.74 0.869 109.40 ± 34.22 127.26 ± 38.80 0.076 
Non-HDL-Cholesterol (mg/dL) † 159.52 ± 31.28 150.97 ± 44.26 0.152 141.97 ± 24.98 169.74 ± 38.15 0.000 
Atherogenic Index † 5.04 ± 1.77 4.37 ± 1.04 0.031 4.86 ± 1.06 5.52 ± 1.63 0.017 
† Paired t-test was used for parametric variables and ‡ Wilcoxon signed rank test for non-parametric 
variables. A p-value ≤ 0.05 was considered statistically significant, marked in bold numbers. 
Table 3. Diet analysis. 
Variable Omega-3 (n = 29) Placebo (n = 25) 
 Basal Final p Basal Final p 
Energy (kcal/day) 1562.2 ± 387.4 1672.8 ± 665.2 0.476 1751.4 ± 479.9 1875.9 ± 698.5 0.276 
Protein (g/day) 57.3 ± 17.2 59.4 ± 24.3 0.737 50.8 ± 19.4 60.5 ± 27.8 * 0.030 
Carbohydrates (g/day) 192.1 ± 60.4 187.8 ± 68.8 0.729 258.2 ± 73.1 255.0 ± 104.7 0.905 
Lipids (g/day) 59.5 ± 21.2 72.2 ± 38.4 0.097 54.2 ± 27.7 65.2 ± 31.1 0.092 
Saturated fatty acids (g/day) 16.4 ± 7.2 19.3 ± 11.9 0.271 11.4 ± 9.0 14.7 ± 9.7 0.065 
Monounsaturated fatty acids (g/day) 20.2 ± 8.2 24.6 ± 15.5 0.160 15.4 ± 10.6 22.6 ± 14.3 * 0.013 
Polyunsaturated fatty acids (g/day) 13.2 ± 8.1 16.5 ± 12.7 0.197 13.2 ± 11.9 13.0 ± 6.4 0.367 
Omega-3 fatty acids (g/day) 0.89 ± 0.76 1.32 ± 0.34 * 0.001 0.79 ± 1.12 0.75 ± 0.53 0.178 
Omega-6 fatty acids (g/day) 10.5 ± 7.7 13.6 ± 12.0 0.221 9.4 ± 11.0 8.8 ± 5.2 0.382 
n6:n3 Ratio 14:1 10:1 * 0.025 16:1 14:1 0.882 
EPA (g/day) 0.077 ± 0.317 0.330 ± 0.018 * 0.000 0.016 ± 0.037 0.047 ± 0.177 0.837 
DHA (g/day) 0.103 ± 0.236 0.287 ± 0.089 * 0.000 0.086 ± 0.109 0.155 ± 0.187 0.074 
Mann–Whitney U test for differences between groups. * A p-value < 0.05 was considered significant, 
marked with bold numbers. 
4. Discussion 
In this study, we investigated the effect of supplementation with n-3 PUFAs on serum levels of 
adiponectin, resistin, and leptin in an adult Mexican population with T2DM.  
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The results of the anthropometric analysis (Table 1) are similar to the results observed in 
previous similar studies such as a study of supplementation with n-3 PUFAs in diabetic patients [22]; 
patients with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) [23]; and two more 
in women with polycystic ovarian syndrome [24,25], which regularly present insulin resistance. All 
of these studies showed no significant change in body weight, BMI, body fat, waist circumference, or 
waist/hip ratio after the supplementation period, even at higher doses of n-3 PUFAs and longer 
periods of supplementation. However, in a crossover model in which 16 T2DM patients were 
assigned to one of two consecutive 3.5-week periods of diabetic diets (foods rich in n-6 or n-3 PUFAs), 
the authors found a slight but significant reduction in body weight and BMI in both dietary periods 
[26]. This suggests that n-3 PUFAs from food are more effective in controlling body weight than n-3 
PUFAs from supplements. In our study, supplementation with n-3 PUFAs for 24 weeks only helped 
to significantly reduce waist circumference and did not help control body weight or reduce BMI, 
body fat percentage, or waist/hip ratio. Furthermore, one of the studies in women with polycystic 
ovarian syndrome reported that effects of n-3 PUFAs on anthropometric measurements might be 
dependent on gender, age, and BMI of subjects at baseline [25].  
The effect of n-3 PUFAs on glucose and glycosylated hemoglobin is not clear. A study of 
supplementation with DHA-rich fish oil in an Iranian diabetic population [27] and reviews of clinical 
trials of supplementation with n-3 PUFAs in different diabetic populations, have not found 
significant positive effects on glycemic control [17,28]. However, a recent study [23] showed that n-3 
PUFA supplementation with high doses for 18 months was effective in reducing glycemia and IR in 
patients affected by IFG or IGT and that the regression of the condition of impaired glycemia to 
normoglycemia seems to be helpful in delaying the development of T2DM. Flanchs et al. showed in 
a review that the beneficial effects of n-3 PUFAs on insulin sensitivity and glucose metabolism in 
people with IR are dependent on factors such as disease progression and age [29]. In this study, we 
found a significant positive effect of n-3 PUFA supplementation on glycemic control (glucose and 
glycosylated hemoglobin), but more studies are needed to test this hypothesis because most of the 
beneficial effects have been shown in epidemiologic studies based on a habitual fish diet consumed 
for years [28]. 
As expected, there were significant reductions in leptin serum levels and hence in 
leptin/adiponectin ratio, which has been demonstrated to be related to obesity and T2DM [29]. 
Contrary to expectation, adiponectin did not increase significantly, while resistin increased 
significantly. Our results are not in line with the results observed in similar studies of 
supplementation with n-3 PUFAs in diabetes [8] and in healthy subjects with a high consumption of 
fish, which has shown significant increases in adiponectin serum levels after various 
supplementation periods [30]. As the changes in adipokine profile were similar in both groups, we 
cannot affirm that higher doses of n-3 PUFAs would have led to a decrease in leptin and 
leptin/adiponectin ratio because there was no lead tendency toward lower leptin concentrations in 
subjects with the n-3 PUFA supplement than in subjects with the placebo. 
Our study population showed higher basal adiponectin and leptin serum levels than have been 
reported in other similar studies, for example, in German [31], Finnish [32], Japanese [8], Asian Indian 
[33], and Arabic diabetic populations [34], which is likely to be due to ethnicity. Resistin showed 
similar results compared with serum resistin levels of Egyptians and Japanese although slightly 
lower [35,36].  
It has been demonstrated that weight reduction increases plasma adiponectin concentrations 
and improves IR [10], but in this study, possibly because there were no significant changes in body 
weight, there were no significant increases in serum adiponectin levels. In a study with ob/ob mice, 
the administration of recombinant adiponectin, even after the development of diabetes, significantly 
ameliorated hyperglycemia [37], and it has been reported that serum adiponectin levels correlate 
inversely with IR [5]. Plasma adiponectin levels have also been demonstrated to be negatively 
correlated to IR [4], but in this study, we did not find a negative correlation because adiponectin (non-
significant) and HOMA-IR increased.  
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Leptin correlates directly with adipose tissue mass; [5] however, we did not observe a significant 
reduction in body weight, BMI, and body fat, despite the reduction in serum leptin levels. When we 
used a bivariate correlation analysis, we found that serum leptin levels showed a positive correlation 
with BMI (R = 0.353 and p = 0.009) and body fat percentage (R = 0.518 and p = 0.000), which is in line 
with the results of a similar study [5]. 
Leptin/adiponectin ratio showed a significant reduction in both groups related to the significant 
decrease in leptin levels. Leptin/adiponectin ratio was a useful measure of IR in non-diabetic white 
adults [38], but we did not observe a positive correlation between HOMA-IR and leptin serum levels; 
despite the reduction in this ratio, there was no reduction in HOMA-IR. However, these findings 
suggest the use of the leptin/adiponectin ratio as a useful tool to detect IR. On the other hand, resistin 
has been linked to obesity and IR since its discovery [12], but our results are not consistent with these 
findings because we found a weak negative correlation between resistin levels and HOMA-IR (R = 
−0.274 and p = 0.045). 
Obesity is the most significant factor contributing to IR and T2DM [39], and although our 
patients were not obese, we found a weak but significant positive correlation between body fat 
percentage and HOMA-IR (R = 0.275 and p = 0.046). This factor might explain the significant increase 
in HOMA-IR in both groups because there was a non-significant increase in body fat percentage. 
Our results are not in accordance with those of Yamamoto et al., who showed in a 
supplementation study with EPA in hyperlipidemic patients that IR determined by the HOMA-IR 
was significantly improved in the supplemented group, compared with the placebo [21]. In our 
study, both groups showed an increase in HOMA-IR, more studies are therefore necessary to 
evaluate only the EPA effect in the IR of individuals with T2DM. 
Our data show an overall improvement in the lipid profile through the atherogenic index in the 
n-3 PUFA supplemented group, with an overall deterioration in the placebo group. Derosa et al. 
found an increase in HDL-cholesterol and a decrease in triacylglycerides after 18 months of 
supplementation with n-3 PUFA, in patients with impaired glucose metabolism [23]. While in 
subjects with type 2 diabetes supplemented with DHA-rich fish oil, Mansoori et al. found a decrease 
in triacylglycerides independently of their initial values [27]. However, several trials of 
supplementation with n-3 PUFA have not found an effect on lipid profile in adults with T2DM [40,41].  
Non-HDL-cholesterol has been recommended as a sensitive proxy of the atherogenic metabolic 
lipid status; importantly, its values in our study population showed a non-significant decrease in the 
supplemented group but a highly significant increase in the placebo group. This may be considered 
a protective effect of n-3 PUFA supplementation on the lipid metabolic deterioration caused by T2DM 
[15, 16].  
With respect to diet analysis, our results are in line with those of a previous study of this group 
that showed that a Mexican population with T2DM had a very low intake of n-3 PUFAs and a high 
consumption of lipids, particularly saturated fatty acids [42]. According to the recommendations of 
the Mexican Official Standard NOM-015-SSA2-2010, for prevention, treatment, and control of 
diabetes mellitus [43], the mean daily energy intake of all groups was adequate, though protein and 
n-3 PUFA intake in both groups and carbohydrate intake in FOG were lower than recommendations, 
while the total lipid intake and saturated fatty acid intake were higher than recommendations in 
FOG.  
It is well known that the quality of dietary fat is a key determinant of IR and that saturated and 
trans fatty acids decrease insulin secretion and worsen insulin sensitivity [10]; a factor which could 
explain the higher increase in HOMA-IR in FOG because of their higher intake of saturated fatty 
acids.  
The quality of fat may have a significant influence on adiponectin concentrations. The data from 
13 studies in a systematic review showed a modest and significant effect of n-3 PUFA 
supplementation on adiponectin concentrations [44]. Because of the very low intake of n-3 PUFAs in 
both our groups, we may not have been able to observe significant changes in adiponectin levels. In 
vitro human adipocyte studies found that EPA and DHA (100 μM) treatment for 48 h, increases 
adiponectin secretion, and that only EPA led to higher cellular adiponectin being introduced into the 
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adipocytes, suggesting that the regulation of adiponectin by n-3 PUFAs is dose- and time-dependent 
and that it can be affected by the maturation stage of adipocytes [9]. However, another study of 
supplementation with n-3 PUFAs in Mexican children and adolescents with obesity and insulin 
resistance, showed that for n-3 PUFAs, the duration of treatment is not associated with the effects 
observed and that the dosage could be more important, which in this case would suggest that in our 
study the n-3 PUFA dose we used can be considered low [45].  
It has been demonstrated that diets high in fish and flaxseed oil lower the serum phospholipid 
ratio of omega-6/omega-3 fatty acids and that n-3 PUFAs are beneficial in patients affected by 
inflammatory diseases. The omega 6/omega 3 ratio is of importance in health and disease; during the 
Paleolithic period of human evolution, there was a different balance between n-6 and n-3, but the last 
150 years have seen a significant increase, as in Western diets this ratio is now in the range of 15–20:1 
[46]. Because of the low intake of n-3 PUFAs and the increased amounts of the n-6 PUFA linoleic acid 
(and high levels found in plasma phospholipids to be published elsewhere) in our study population, 
the omega 6/omega 3 ratios were of 11:1 and of 13:1 in FOG and PG, respectively, very similar to 
Western diets [47]. 
Although we found a beneficial effect of EPA + DHA supplementation on waist circumference, 
glucose, glycosylated hemoglobin, leptin, and leptin/adiponectin ratio in this population, these 
beneficial effects may not have been due to the supplement alone because we observed similar results 
in some of these parameters between patients who took the n-3 PUFA supplement and those that 
took the placebo. Similarly, there were significant increases in resistin, serum insulin, and HOMA-IR 
in both groups. It is possible that some of the beneficial effects observed in both groups were due to 
metformin and that the combined use of n-3 PUFA and metformin gave rise to better outcome 
measures. However, the significant increase in monounsaturated fatty acids and protein in the 
placebo group may also have contributed to the decrease in glycosylated hemoglobin, leptin, and 
leptin/adiponectin ratio and the increase in resistin, insulin, and HOMA-IR in this group. 
Interestingly, Schwingshack et al., 2001, and McAllan et al., 2014, have reported that macronutrient 
quality and composition, i.e. monounsaturated fat and protein can affect some of the parameters we 
have measured (leptin and glycosylated hemoglobin) and in the same direction we observed for the 
placebo group [48,49]. 
5. Conclusions 
Additional research is required to fully understand the associated mechanisms between n-3 
PUFA-rich fish oil consumption and adipokine secretion/expression. The small sample size and use 
of metformin may have limited our findings as well as the use of a relatively low dose of n-3 PUFAs, 
so larger studies with higher doses of n-3 PUFAs are required to confirm and extend our findings. It 
would be important to measure serum levels of other adipokines related to IR and T2DM, such as 
visfatin and apelin, to determine if the beneficial effects of PUFA n-3 are sustained after the cessation 
of therapy and to determine if negative effects on insulin sensitivity are actually caused by the 
supplement. The different effects of EPA and DHA observed in some studies highlight the need to 
study their actions separately.  
In summary and despite the limitations, our study is the first to report serum concentrations of 
adiponectin, resistin, and leptin and show a beneficial effect of n-3 PUFA supplementation on waist 
circumference, glucose, glycosylated hemoglobin, leptin, and leptin/adiponectin ratio and lipid 
profile in a group of Mexican individuals with T2DM. Supplementation with n-3 PUFA and n-3 PUFA 
combined with metformin both warrant further investigation in Mexican T2DM.  
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